Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) and Evofem Biosciences (NASDAQ:EVFM – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.
Analyst Recommendations
This is a summary of recent ratings and target prices for Vanda Pharmaceuticals and Evofem Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vanda Pharmaceuticals | 1 | 2 | 5 | 0 | 2.50 |
| Evofem Biosciences | 0 | 0 | 0 | 0 | 0.00 |
Vanda Pharmaceuticals presently has a consensus target price of $13.70, suggesting a potential upside of 159.47%. Given Vanda Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Evofem Biosciences.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vanda Pharmaceuticals | $216.10 million | 1.48 | -$220.47 million | ($4.63) | -1.14 |
| Evofem Biosciences | $11.39 million | 0.09 | $52.98 million | ($0.13) | -0.06 |
Evofem Biosciences has lower revenue, but higher earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Vanda Pharmaceuticals has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -1.32, suggesting that its share price is 232% less volatile than the S&P 500.
Profitability
This table compares Vanda Pharmaceuticals and Evofem Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vanda Pharmaceuticals | -127.41% | -49.81% | -33.29% |
| Evofem Biosciences | -46.42% | -91.97% | -61.93% |
Summary
Vanda Pharmaceuticals beats Evofem Biosciences on 10 of the 14 factors compared between the two stocks.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company’s pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
About Evofem Biosciences
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
